Chardan Capital Boosts Hyperion DeFi (NASDAQ:HYPD) Price Target to $8.25

Hyperion DeFi (NASDAQ:HYPD) had its price target upped by investment analysts at Chardan Capital from $7.75 to $8.25 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target suggests a potential upside of 136.39% from the company’s current price.

HYPD has been the subject of a number of other research reports. Cantor Fitzgerald initiated coverage on shares of Hyperion DeFi in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 target price on the stock. Zacks Research raised shares of Hyperion DeFi to a “hold” rating in a research note on Monday, December 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Hyperion DeFi has an average rating of “Hold” and a consensus price target of $6.13.

Hyperion DeFi Stock Performance

HYPD opened at $3.49 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The stock has a market capitalization of $28.52 million, a price-to-earnings ratio of -0.86 and a beta of 2.74. The company has a fifty day moving average of $3.47 and a 200 day moving average of $5.32. Hyperion DeFi has a fifty-two week low of $0.85 and a fifty-two week high of $17.18.

Hyperion DeFi (NASDAQ:HYPD) last posted its earnings results on Thursday, March 26th. The company reported ($7.76) EPS for the quarter. The firm had revenue of $0.50 million during the quarter. As a group, sell-side analysts forecast that Hyperion DeFi will post -41.6 earnings per share for the current fiscal year.

Insider Activity at Hyperion DeFi

In related news, Director Ellen R. Strahlman bought 11,856 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was bought at an average cost of $3.61 per share, for a total transaction of $42,800.16. Following the purchase, the director directly owned 34,869 shares of the company’s stock, valued at approximately $125,877.09. This trade represents a 51.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO David R. Knox acquired 27,950 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were bought at an average cost of $3.59 per share, for a total transaction of $100,340.50. Following the completion of the acquisition, the chief financial officer directly owned 327,950 shares of the company’s stock, valued at approximately $1,177,340.50. The trade was a 9.32% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 51,918 shares of company stock valued at $186,744. 10.86% of the stock is owned by insiders.

Institutional Trading of Hyperion DeFi

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new stake in shares of Hyperion DeFi in the fourth quarter worth about $663,000. Jane Street Group LLC acquired a new stake in shares of Hyperion DeFi during the 4th quarter worth approximately $493,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Hyperion DeFi during the 4th quarter worth approximately $221,000. Geode Capital Management LLC purchased a new position in shares of Hyperion DeFi during the 4th quarter valued at approximately $214,000. Finally, Investment House LLC acquired a new position in shares of Hyperion DeFi in the 4th quarter valued at $166,000. 25.84% of the stock is owned by hedge funds and other institutional investors.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.